View Older Stories View More Recent Stories

Jun 1, 2023 09:15AM TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
May 31, 2023 07:40AM TG Therapeutics (TGTX) Announces Data from ULTIMATE I & II Phase 3 Trials of BRIUMVI in Multiple Sclerosis to be Presented at CMSC
May 31, 2023 07:30AM TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers An
May 4, 2023 07:30AM TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
May 1, 2023 07:30AM TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Apr 28, 2023 04:30PM TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
Apr 27, 2023 07:30AM TG Therapeutics (TGTX) Announces Issuance of Permanent J-Code for BRIUMVI
Apr 27, 2023 07:30AM TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
Apr 25, 2023 08:00AM TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meetin
Mar 31, 2023 07:31AM TG Therapeutics (TGTX) Announces Positive CHMP Opinion for BRIUMVI for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Mar 31, 2023 07:30AM TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Mar 3, 2023 08:31AM TG Therapeutics (TGTX) Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI
Mar 3, 2023 08:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75t
Feb 28, 2023 07:30AM TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
Feb 24, 2023 07:30AM TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
Feb 24, 2023 07:01AM TG Therapeutics (TGTX) Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI
Feb 24, 2023 07:00AM TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research i
Feb 14, 2023 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and R
Jan 26, 2023 07:08AM TG Therapeutics (TGTX) Announces Commercial Launch of BRIUMVI
Jan 26, 2023 07:00AM TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
Jan 6, 2023 07:30AM TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 28, 2022 01:49PM TG Therapeutics (TGTX) Confirms FDA Approval of BRIUMVI (ublituximab-xiiy)
Dec 28, 2022 01:48PM TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
Nov 10, 2022 07:30AM TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Nov 8, 2022 07:30AM TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update
Oct 26, 2022 07:30AM TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment a
Oct 13, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research
Sep 9, 2022 07:30AM TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug 25, 2022 07:31AM TG Therapeutics (TGTX) Reports Publication of Results from ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab
Aug 25, 2022 07:30AM TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
Aug 8, 2022 07:30AM TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Aug 5, 2022 07:30AM TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update
Jun 27, 2022 07:31AM TG Therapeutics (TGTX) Reports Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab
Jun 27, 2022 07:30AM TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
Jun 3, 2022 07:30AM TG Therapeutics (TGTX) Presents Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab
Jun 3, 2022 07:30AM TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Ann
May 31, 2022 07:30AM TG Therapeutics (TGTX) Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
May 31, 2022 07:30AM TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
May 26, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annua
May 20, 2022 07:30AM TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Apr 26, 2022 07:30AM TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
Apr 18, 2022 09:23AM Pre-Open Stock Movers 04/18: Casa Systems and Natus Medical Higher; TG Therapeutics and Nektar Lower (more...)
Apr 15, 2022 08:31AM TG Therapeutics (TGTX) Voluntarily Withdraws BLA/sNDA for U2 to Treat Patients with CLL and SLL
Apr 15, 2022 08:30AM TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
Apr 6, 2022 07:30AM TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
Apr 4, 2022 07:44AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
Mar 10, 2022 08:16AM TG Therapeutics (TGTX) Announces FDA Set ADCOM Meeting for April 22, 2022
Mar 10, 2022 08:15AM TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
Mar 4, 2022 07:31AM TG Therapeutics (TGTX) Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
Mar 4, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
View More Recent Stories View Older Stories